Royal Bank of Canada
RANI icon

Royal Bank of Canada’s Rani Therapeutics RANI Stock Holding History

Royal Bank of Canada’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
132
+5
+4% +$6 ﹤0.01% 7584
2025
Q4 		$0 Buy
127
+88
+226% +$133 ﹤0.01% 7545
2025
Q3 		$0 Buy
39
+8
+26% +$4 ﹤0.01% 7443
2025
Q2 		$0 Buy
+31
New +$25 ﹤0.01% 7284
2024
Q3 		– Sell
-12
Closed – – 7323
2024
Q2 		$0 Hold
12
– – ﹤0.01% 7444
2024
Q1 		$0 Hold
12
– – ﹤0.01% 7481
2023
Q4 		$0 Sell
12
-31
-72% -$72 ﹤0.01% 7493
2023
Q3 		$0 Sell
43
-44
-51% -$168 ﹤0.01% 7474
2023
Q2 		$0 Hold
87
– – ﹤0.01% 7580
2023
Q1 		$0 Hold
87
– – ﹤0.01% 7399
2022
Q4 		$1K Sell
87
-2
-2% -$15 ﹤0.01% 7070
2022
Q3 		$1K Buy
89
+62
+230% +$657 ﹤0.01% 7248
2022
Q2 		$0 Hold
27
– – ﹤0.01% 7653
2022
Q1 		$0 Buy
+27
New +$448 ﹤0.01% 7961

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Royal Bank of Canada's RANI Position: Q1 2026 in Review

Royal Bank of Canada increased its Rani Therapeutics (RANI) stake by 3.9% in Q1 2026, buying an estimated $6 and bringing the position to 132 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7584.

Royal Bank of Canada first reported a position in RANI in Q1 2022 and has held it in 14 quarters since. The position peaked at $1K in Q4 2022. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Royal Bank of Canada held 132 shares of Rani Therapeutics worth $0 as of Q1 2026.
  • Royal Bank of Canada bought 5 Rani Therapeutics shares in Q1 2026, an estimated $6.
  • Rani Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7584 holding.
  • Royal Bank of Canada first reported a position in Rani Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • Royal Bank of Canada's Rani Therapeutics position peaked at $1K in Q4 2022.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.